What Is Vilon?
Vilon is a synthetic dipeptide containing lysine and glutamic acid, usually written Lys-Glu or KE. It comes from the Russian short-peptide bioregulator programme associated with research on Thymalin, a calf-thymus polypeptide extract.
Published work concerns immune cells, chromatin, gene expression, cellular ageing and blood-coagulation markers. Most evidence comes from laboratory experiments and a small connected research network. Human reports are sparse and often lack the detail needed to assess randomisation, comparison groups and adverse events.
Vilon is not approved by the United States Food and Drug Administration, the United Kingdom Medicines and Healthcare products Regulatory Agency or the European Medicines Agency. Claims that it restores immunity or slows human ageing go beyond the evidence.
What kind of molecule is Vilon?
Vilon contains two amino-acid residues:
`Lys-Glu`
Lysine has a positively charged side chain and glutamic acid has an acidic side chain. The letters KE are their international one-letter codes. A dipeptide contains one peptide bond and is far smaller than most signalling proteins.
Short length makes chemical identity easier to define, but it does not establish tissue targeting. Vilon is also called the KE peptide in papers. It should not be confused with ordinary dietary lysine and glutamic acid, because researchers attribute the proposed activity to the intact sequence.
How is Vilon connected to Thymalin?
Thymalin is an animal-derived mixture. Researchers studying that preparation proposed that short motifs could reproduce selected regulatory effects. KE became Vilon, a chemically defined synthetic molecule.
Evidence cannot be transferred automatically between them. The extract contains many components, while Vilon contains only two residues. Each requires its own exposure, safety and efficacy evidence.
How was Vilon developed?
| Period | Development |
|---|---|
| 1970s onward | Soviet researchers developed thymus-derived peptide preparations including Thymalin |
| Late twentieth century | Short synthetic sequences were proposed as defined tissue-regulating compounds |
| Early 2000s | Studies examined Vilon in human thymus-cell cultures, chromatin and clinical laboratory markers |
| 2020s | Research focused on gene and protein expression in ageing cell models |
| Current position | Laboratory research compound with limited human reporting and no Western regulatory approval |
This is not a conventional Phase I, II and III development programme. No published Phase I study clearly establishes initial human exposure, pharmacokinetics and dose-limiting adverse effects.
What did the thymus-cell study show?
Researchers cocultured Vilon with human thymocytes, which are developing T cells, and thymic epithelial cells, which help guide their maturation. The study measured argyrophilic proteins in nucleolar organiser regions. These proteins are associated with ribosome production and cellular protein synthesis.
Vilon increased the measured signal and promoted transformation of some thymocytes into proliferating blast cells. A blast cell is an activated, dividing immune-cell form.
This was a cell-culture result. Increased proliferation is not proof of better immunity and could be helpful, neutral or harmful depending on the cells and context.
What does the chromatin research mean?
Chromatin is DNA packaged with proteins inside the cell nucleus. Tightly packed heterochromatin is generally less accessible for gene transcription. One study reported that Vilon increased decondensation of facultative heterochromatin in lymphocytes from older people.
Decondensation may permit some genes to become more active, but the experiment does not show that every change is beneficial or that cellular ageing has been reversed. Broad chromatin effects also create questions about selectivity.
Later studies reported changes in SIRT1, PARP1 and PARP2 expression in ageing human mesenchymal stem cells. These proteins participate in stress responses and DNA repair. Changes in their expression are biomarkers, not evidence of longer life or reduced disease.
What human evidence exists?
A Russian report studied coagulation and fibrinolysis in people of different ages with type 1 diabetes. Coagulation forms blood clots; fibrinolysis breaks them down. The authors described reduced laboratory signs associated with disseminated intravascular coagulation after Vilon was added to usual treatment.
The accessible abstract does not provide enough detail about participant numbers, random allocation, masking, comparison groups or clinical events. It therefore cannot establish that Vilon prevents thrombosis, bleeding or diabetes complications.
Laboratory clotting markers are surrogate outcomes. A useful treatment must improve patient outcomes without causing bleeding or other harm.
Does Vilon slow ageing?
No reliable human trial shows slower ageing, fewer age-related diseases or longer survival. Chromatin opening and altered expression of ageing-associated proteins are mechanistic observations.
Cellular senescence, DNA repair, inflammation and organ function interact in complex ways. Moving one marker in cultured cells cannot establish whole-body rejuvenation.
How is Vilon synthesised and characterised?
Vilon can be made by solid-phase peptide synthesis using protected lysine and glutamic-acid building blocks. Protecting groups prevent their side chains from reacting at the wrong position. After coupling, the molecule is released, deprotected and purified.
Both amino acids contain reactive side chains, so identity testing must confirm the intended bond rather than an isomer. Mass spectrometry, nuclear magnetic resonance, chromatographic related-substance analysis, chiral testing and peptide-content measurement can form part of quality control.
Any sterile investigational formulation also needs validated sterility, bacterial-endotoxin, particle, concentration and stability controls. A purity percentage alone does not establish pharmaceutical quality.
What is known about pharmacokinetics and safety?
No well-described modern human study defines absorption, intact-peptide half-life, tissue distribution, metabolism or clearance. Dipeptides may be transported intact or rapidly broken into amino acids.
The human safety record is too limited to define common or uncommon adverse effects. Potential concerns include immune imbalance, unintended gene-regulatory effects, altered coagulation and impurities in unverified material. These are questions requiring study, not established adverse reactions.
Is Vilon approved?
Vilon is not approved by the FDA, MHRA or EMA for immune dysfunction, diabetes, ageing or any other indication. Research history or sale under a peptide-bioregulator label does not establish regulatory approval.
How strong is the evidence overall?
| Question | Best available evidence | Defensible conclusion |
|---|---|---|
| Does Vilon affect cultured immune cells? | Human thymus-cell experiments | Cellular effects were reported |
| Does it alter chromatin or gene markers? | Lymphocyte and stem-cell studies | Selected laboratory markers changed |
| Does it improve coagulation in diabetes? | Poorly detailed clinical report | Clinical benefit is not established |
| Does it slow human ageing? | No confirmatory trial | No evidence |
| Is it safe in people? | Sparse reporting | Not established |
| Is it approved? | No FDA, MHRA or EMA approval | No |
Frequently asked questions
What is Vilon made of?
Lysine and glutamic acid, joined as the dipeptide Lys-Glu.
Is Vilon the same as Thymalin?
No. Thymalin is a calf-thymus peptide mixture; Vilon is one defined synthetic dipeptide.
Is it the same as Thymogen?
No. Thymogen is Glu-Trp, while Vilon is Lys-Glu.
Does Vilon stimulate T cells?
It increased proliferation-related measures in cultured thymocytes. That does not establish improved immunity in people.
Does it change gene expression?
Laboratory studies report changes in chromatin and selected proteins, but the clinical meaning is unknown.
Does Vilon prevent blood clots?
No controlled outcome trial establishes clot prevention.
Does Vilon reverse ageing?
No. Cell markers cannot demonstrate reversal of human ageing.
Has Vilon been tested in humans?
Limited Russian human reporting exists, but it is insufficient for firm efficacy or safety conclusions.
Is Vilon known to be safe?
No comprehensive modern human safety profile exists.
Is Vilon approved?
It is not approved by the FDA, MHRA or EMA.
Sources
Research reviewed through October 2026.